218 related articles for article (PubMed ID: 8115994)
1. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial.
Pieters H; Roodt JP; Badenhorst PN; van Wyk V; Schall R; Lötter MG; Hundt HK; Nel CJ
Thromb Haemost; 1993 Dec; 70(6):903-8. PubMed ID: 8165609
[TBL] [Abstract][Full Text] [Related]
3. [Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
Cissé-Thiam M; Drouet L
Dakar Med; 1999; 44(1):25-7. PubMed ID: 10797981
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo inhibition of platelet aggregation in patients with severe limb arteriopathy treated with BAY U3405, a specific TX A2 receptor antagonist.
Bellucci S; Kedra W; Groussin H; Jaillet N; Molho-Sabatier P; Andreassian B; Tobelem G
Thromb Haemost; 1994 Nov; 72(5):659-62. PubMed ID: 7900069
[TBL] [Abstract][Full Text] [Related]
5. [Effect of BAY u3405-thromboxane A2 receptor antagonist, on biphasic airway responses induced by platelet-activating factor in actively sensitized guinea pigs].
Arima M; Yukawa T; Fukuda T; Makino S
Arerugi; 1995 Jul; 44(7):701-7. PubMed ID: 7575136
[TBL] [Abstract][Full Text] [Related]
6. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons.
Kotzé HF; Lamprecht S; Badenhorst PN; Roodt JP; van Wyk V
Thromb Haemost; 1997 Jun; 77(6):1137-42. PubMed ID: 9241746
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y; Asai F; Wada K; Nakashima M
Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
[TBL] [Abstract][Full Text] [Related]
8. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
9. Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time.
Mazur C; Tschopp JF; Faliakou EC; Gould KE; Diehl JT; Pierschbacher MD; Connolly RJ
J Lab Clin Med; 1994 Oct; 124(4):589-99. PubMed ID: 7523555
[TBL] [Abstract][Full Text] [Related]
10. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
[TBL] [Abstract][Full Text] [Related]
11. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
12. Studies of suloctidil in experimental thrombosis in baboons.
Hanson SR; Harker LA
Thromb Haemost; 1985 Jun; 53(3):423-7. PubMed ID: 2996168
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
Takiguchi Y; Wada K; Nakashima M
Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
[TBL] [Abstract][Full Text] [Related]
15. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
16. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
[TBL] [Abstract][Full Text] [Related]
17. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
Fiedler VB; Perzborn E; Seuter F; Rosentreter U; Böshagen H
Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
[TBL] [Abstract][Full Text] [Related]
18. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies on the effect of thromboxane receptor blockade on platelet deposition on vascular surfaces.
Xia G; Lindberg K; Risberg B
Thromb Res; 1994 May; 74(3):233-42. PubMed ID: 8042191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
